Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / Diseases and Disorders / Prostate Cancer / January 2006

Tip: Looking for answers? Try searching our database.

Margins

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
Thomas Traub - 15 Jan 2006 14:56 GMT
One of the margins showed up positive on the pathology report after my RRP.
My uro said that it is not uncommon to get a false reading.  Anyone's
thoughts about this would be appreciated.
ron - 15 Jan 2006 16:19 GMT
> One of the margins showed up positive on the pathology report after my RRP.
> My uro said that it is not uncommon to get a false reading.  Anyone's
> thoughts about this would be appreciated.

Tom...Not sure what the uro meant by "false reading."  When a
pathologist examines the removed prostate, he pays particular attention
to see if there are any cancerous cells present right where the knife
detached the prostate from surrounding tissue (the margin).  Cancerous
cells are either present or not present at the margin.  As Walsh points
out, cancerous cells, even if present at the margin, may not extend
into the healthy remaining tissue.  Or if they do extend into remaining
tissue, the surgical procedure could have killed (disrupted) those
remaining cells, if only small numbers were involved.  I think that "on
average" positive margins occur around 15% of the time, give or take.
Obviously some surgeons encounter them more often than others.
Typically, positive margins increase in frequency as patient staging
advances.  Much has been written about the effect of positive margins
upon recurrence.  While authors have argued both ways (positive margins
mean nothing / mean something in terms of recurrence), recent articles
seem to lean in the direction that there is some correlation between
margins and recurrence, see the abstracts below...Best wishes and good
health, Ron

J Urol. 2005 Sep;174(3):903-907

DO MARGINS MATTER? THE PROGNOSTIC SIGNIFICANCE OF POSITIVE SURGICAL
MARGINS IN RADICAL PROSTATECTOMY SPECIMENS.

Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K,
Scardino PT.

>From the Department of Urology, Memorial Sloan-Kettering Cancer Center,
Sidney Kimmel Center for Prostate and Urologic Cancer, New York, New
York (PS, JAE, MO, MWK, PTS), and the Departments of Urology and
Pathology, Baylor College of Medicine, Houston, Texas (TW, NM, KS).

PURPOSE: The prognostic significance of positive surgical margins (PSM)
in radical prostatectomy (RP) specimens remains unclear. While most
studies have concluded that a PSM is an independent adverse prognostic
factor, others report that surgical margin status has no effect on
prognosis. One reason for these discordant conclusions is the variable
number of patients with a PSM who receive adjuvant therapy and the
differing statistical methods used to account for the effects of the
time course of adjuvant treatment on recurrence. We evaluated the
prognostic significance of PSMs using multiple methods of analysis
accounting for patients who received adjuvant therapy.
MATERIALS AND METHODS: We analyzed 1,389 consecutive patients with
clinical stage T1-3 prostate cancer treated with RP by 2 surgeons from
1983 to 2000. Of 179 patients with a PSM, 37 received adjuvant therapy
(AT), 29 radiation therapy and 8 received hormonal therapy. Because the
method used to account for men receiving AT can affect the outcome of
the analysis, data were analyzed by the Cox proportional hazards
technique accounting for patients receiving AT using 5 methods: 1)
exclusion, 2) inclusion (AT ignored), 3) censoring at time of AT, 4)
failing at time of AT and 5) considering AT as a time dependent
covariate.
RESULTS: Overall 179 patients (12.9%) had a PSM, including 6.8% of 847
patients with pT2 and 23% of 522 patients with pT3 disease. A PSM was a
significant predictor of cancer recurrence when analyzed using methods
1, 3, 4 and 5 (p=0.005, p=0.014, p=0.0005, p=0.002, respectively).
However, it was not a predictor of recurrence using method 2 in which
AT was ignored (p=0.283). Using method 5 multivariate analysis
demonstrated that a PSM (p=0.002) was an independent predictor of
10-year progression-free probability (PFP) along with Gleason score
(p=0.0005), extracapsular extension (p=0.0005), seminal vesicle
invasion (p <0.0005), positive lymph nodes (p <0.0005) and preoperative
serum prostate specific antigen (p <0.0001). Using method 5 the 10-year
PFP was 58% +/- 12% and 81% +/- 3% for patients with and without a PSM,
respectively (p <0.00005). The relative risk of recurrence in men with
a PSM using method 5 was 1.52 (95% confidence interval 1.06-2.16).
CONCLUSIONS: We confirm that a PSM has a significant adverse impact on
PFP after RP in multivariate analysis using multiple statistical
methods to account for patients who received AT. While prostate cancer
screening strategies have resulted in a majority of men having organ
confined disease at RP, surgeons should continue to strive to reduce
the rate of positive surgical margins to improve cancer control
outcomes.
PMID: 16093984

J Clin Pathol. 2005 Oct;58(10):1028-32

The influence of extent of surgical margin positivity on prostate
specific antigen recurrence.

Emerson RE, Koch MO, Jones TD, Daggy JK, Juliar BE, Cheng L.

Department of Pathology and Laboratory Medicine, Indiana University
School of Medicine, Indianapolis, Indiana, IN 46202, USA.

BACKGROUND: Positive surgical margins are an adverse prognostic factor
in patients undergoing prostatectomy for prostate cancer. The extent of
margin positivity varies and its influence on clinical outcome is
uncertain.AIMS: To evaluate the linear extent of margin positivity and
the number and location of positive sites as prognostic indicators in a
series of prostatectomy specimens evaluated with the whole mount
technique.

METHODS: Eighty six consecutive margin positive prostatectomy specimens
were evaluated, and all pathology data were collected prospectively.
The linear extent of margin positivity was measured with an ocular
micrometer and the total extent of all positive sites was summed. The
total number of sites with positive margins and anatomical sites of the
positive margins were analysed.

RESULTS: The linear extent of margin positivity ranged from 0.01 to 68
mm (mean, 6.8; median, 3.0) and was associated with prostate specific
antigen (PSA) recurrence in univariate logistic regression (p = 0.031).
In addition, the extent of margin positivity weakly correlated with
preoperative PSA (p = 0.017) and tumour volume (p = 0.013), but not
with age, prostate weight, Gleason score, pathological stage, or
perineural invasion. The total number of positive sites was
significantly higher in patients with PSA recurrence (p = 0.037). The
location of the positive margin site was not associated with PSA
recurrence. The extent of margin positivity correlated with PSA
recurrence in univariate analysis, although it had only marginal
predictive value when adjusted for Gleason score (p = 0.076).

CONCLUSIONS: The extent of margin positivity correlates with PSA
recurrence in univariate analysis, although it has no predictive value
independent of Gleason score.
PMID: 16189146
Steve Kramer - 15 Jan 2006 16:51 GMT
Sounds like a bunch of bovine feces to me.  You had an RRP.  That means your
doc took it out whole and they sliced it and diced it in a lab.  If it's
positive, they go back and look at it -- probably twice.  If it's negative,
they probably go back an dlook at it.  It's not like a pregnancy tester
where the sample is gone...  or like a PSA that has a spike.

Biopsies do not show false positives.  If your uro doesn't know, then he or
the lab screwed something up.

Of course, I am not a doc or a lab technician, so take it for what it's
worth.

Signature

PSA 16 10/17/2000 @ 46
Biopsy 11/01/2000 G7 (3+4), T2c
RRP 12/15/2000 G7 (3+4), T3cN0M0 Neg margins
PSA  .1  .1  .1  .27  .37  .75
EBRT 05-07/2002 @ 47
PSA  .34 .22 .15 .21 .32
Lupron 07/03 (1 mo) 8/03 (4 mo), 12/03, 4/04, 09/04, 01/05, 5/05, 10/05
PSA  .07 .05 .06 .05 .08
Non Illegitimi Carborundum

> One of the margins showed up positive on the pathology report after my
> RRP. My uro said that it is not uncommon to get a false reading.  Anyone's
> thoughts about this would be appreciated.
Leonard Evens - 15 Jan 2006 17:05 GMT
> One of the margins showed up positive on the pathology report after my RRP.
> My uro said that it is not uncommon to get a false reading.  Anyone's
> thoughts about this would be appreciated.

Note that the article posted by ron, in his response, says that margin
status did correlate with the likelihood of recurrence, but that it has
no predictive value independent of pathological gleason score.  That
means for example that if you had a Gleason 7=3+4 and a positive margin
and I had a Gleason 7=3+4 with negative margins, then we are both
equally likely to have a recurrence.   Remember also, that any single
study is not definitive.
Bill - 16 Jan 2006 15:13 GMT
Perhaps what the doctor meant (they tend to oversimplify because they
assume we are stupid and know nothing) was that a positive margin does
not necessarily mean that PCa has "escaped the capsule," that PCa cells
are loose in your body, or that you should be overly concerned about it
at this point. The silver lining, well silver plate, is that recurrence
w/ positive margins is more likely to local only and still curative.

Bill Denton
RP 2/12/02
PSA >.6
Memphis
Thomas Traub - 16 Jan 2006 17:40 GMT
If I am going to need radiation, I'm sure they will have a good idea where
to aim it.  At least the main bad actor (the prostate) is gone and can't
cause any more trouble.

> Perhaps what the doctor meant (they tend to oversimplify because they
> assume we are stupid and know nothing) was that a positive margin does
[quoted text clipped - 7 lines]
> PSA >.6
> Memphis
Steve Kramer - 16 Jan 2006 22:07 GMT
Traditionally, they aim it at the prostate bed.  Thanks to PSA, they know
it's there before it can be seen, so they take the chance that the most
likely place for it is the prostate bed.

Signature

PSA 16 10/17/2000 @ 46
Biopsy 11/01/2000 G7 (3+4), T2c
RRP 12/15/2000 G7 (3+4), T3cN0M0 Neg margins
PSA  .1  .1  .1  .27  .37  .75
EBRT 05-07/2002 @ 47
PSA  .34 .22 .15 .21 .32
Lupron 07/03 (1 mo) 8/03 (4 mo), 12/03, 4/04, 09/04, 01/05, 5/05, 10/05
PSA  .07 .05 .06 .05 .08
Non Illegitimi Carborundum

> If I am going to need radiation, I'm sure they will have a good idea where
> to aim it.  At least the main bad actor (the prostate) is gone and can't
[quoted text clipped - 11 lines]
>> PSA >.6
>> Memphis
Alan Meyer - 16 Jan 2006 20:07 GMT
> ...
> Note that the article posted by ron, in his response, says that margin status did
[quoted text clipped - 3 lines]
> then we are both equally likely to have a recurrence.   Remember also, that any single
> study is not definitive.

Leonard,

What's the right way to read this sentence:

   "... Using method 5 multivariate analysis demonstrated that a
   PSM (p=0.002) was an independent predictor of 10-year
   progression-free probability (PFP) along with Gleason score
   (p=0.0005), extracapsular extension (p=0.0005), seminal
   vesicle invasion (p <0.0005), positive lymph nodes (p
   <0.0005) and preoperative serum prostate specific antigen (p
   <0.0001). "

Does that mean that if you hold all of these variables constant except
one, variations in that one predict different progression free
probabilities?

The next reference to Gleason says:

   "The linear extent of margin positivity ranged from 0.01 to
   68 mm (mean, 6.8; median, 3.0) and was associated with
   prostate specific antigen (PSA) recurrence in univariate
   logistic regression (p = 0.031).  In addition, the extent of
   margin positivity weakly correlated with preoperative PSA (p
   = 0.017) and tumour volume (p = 0.013), but not with age,
   prostate weight, Gleason score, pathological stage, or
   perineural invasion."

I presume that means that the extent of positive margins is
somewhat associated with pre-op PSA and tumor volume, but not
with Gleason score or the other named factors.  In other words,
having a high or low Gleason would not, by itself, predict
whether you are likely to have positive margins.

Finally:

   "The extent of margin positivity correlated with PSA
   recurrence in univariate analysis, although it had only
   marginal predictive value when adjusted for Gleason score (p
   = 0.076)."

I interpret this to mean that Gleason is as good a predictor of
pregression free probability as positive margins, and adding the
two together gives us only a marginal improvement in our ability
to predict long term outcome.

Have I got all that right?  If I do, then maybe the way to resolve
the apparent contradiction between the first and last quotes is
that Gleason and PSM independently predict progression free
probability, but they still tend to vary together, i.e., people with
PSM are likely to have high Gleason scores and vice versa.

Does that make statistical sense?  Maybe not :(

Thanks.

   Alan
Leonard Evens - 16 Jan 2006 23:09 GMT
>>...
>>Note that the article posted by ron, in his response, says that margin status did
[quoted text clipped - 19 lines]
> one, variations in that one predict different progression free
> probabilities?

Roughly that is what it means.   But to be sure, I would have to look at
the particular multivariate analysis scheme they are using.

> The next reference to Gleason says:
>
[quoted text clipped - 12 lines]
> having a high or low Gleason would not, by itself, predict
> whether you are likely to have positive margins.

Yes.  But note that they were using a different statistical method to
draw that conclusion.   It is possible for different methods to come up
with apparently contradictory results.   The contradictions arise
because the statistics says something very precise in a mathematical
sense about the study population, but that drawing conclusions beyond
that requires some assumptions and often one doesn't have a good idea of
whether those assumptions are valid.

> Finally:
>
[quoted text clipped - 7 lines]
> two together gives us only a marginal improvement in our ability
> to predict long term outcome.

That is right.  Note that this appears to contradict the earlier
statement.  One would have to look in detail at how the statistics was
done to explain why it isn't a contradiction.

> Have I got all that right?  If I do, then maybe the way to resolve
> the apparent contradiction between the first and last quotes is
> that Gleason and PSM independently predict progression free
> probability, but they still tend to vary together, i.e., people with
> PSM are likely to have high Gleason scores and vice versa.

I think the point is that two variables can appear to be more
"independent" when part of  a larger set of variables pulled out of one
kind of analysis but still somewhat correlated when compared one to the
other in another kind of analysis.

I've seen this sort of thing happen before, and I tried to understand it
all in the distant past. Multivariate analysis is an area fraught with
difficulties and controversies.   Biomedical researchers use statistical
packages, but they seldom understand the theory underlying the tests
they use.   I haven't thought about any of this for quite a while, but
my impression back when I did is that the only way to get a sensible
result from a dataset is to go back to basics, pose a specific
meaningful question which makes sense in the context and then choose a
statistical method which is tailored to question you want to ask.  In
addition, one should be very careful not claim anything beyond what one
has actually shown.  For example, Suppose you have shown that if you
find that in a study population of pateints who died of prostate cancer
within a 10 year period who were diagnosed in the first five years of
the period, that compared to a cancer free population, there was no
greater use of PSA testing.   You should not conclude from this that PSA
testing has no value in reducing mortality from prostate cancer.  The
reason is that you don't know what the results would have been if you
used a 20 year period with diagnosi in the first 15 years or some other
time schedule.
Results tend to apply just to the specific question asked and just to
the population studied.  One can go easily astray by generalizing to
other questions and the population at large.  The questions may seem to
be the same intutitively, but in fact they may be very different when
you look at the details.

I remember when one of my psychology colleagues tried to determine
whether quality of instruction as perceived by students in
questionnaires was a factor in performance on a common final.   The
first year he did the study,  using one of the standard multivariate
analysis packages he concluded it was a significant factor.  The next
year he did the study again on the next year's crop of calculus students
and discovered in was not a significant factor.   My conclusion was that
one should take all such studies with more than a grain of salt.  I
think one needs repeated studies and a good understanding at a
phenomenological level of what is being studied before drawing firm
conclusions.

> Does that make statistical sense?  Maybe not :(
>
> Thanks.
>
>     Alan
Alan Meyer - 17 Jan 2006 01:21 GMT
Thanks Leonard.  That was very helpful.

   Alan
 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2008 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.